HSV and glycoprotein J inhibit caspase activation and apoptosis induced by granzyme B or Fas.
HSV-1 inhibits apoptosis of infected cells, presumably to ensure that the infected cell survives long enough to allow completion of viral replication. Because cytotoxic lymphocytes kill their targets via the induction of apoptosis, protection from apoptosis could constitute a mechanism of immune evasion for HSV. Several HSV genes are involved in the inhibition of apoptosis, including Us5, which encodes glycoprotein J (gJ). Viruses deleted for Us5 showed defects in inhibition of caspase activation after Fas ligation or UV irradiation. Transfected cells expressing the Us5 gene product gJ were protected from Fas- or UV-induced apoptosis, as measured by morphology, caspase activation, membrane permeability changes, or mitochondrial transmembrane potential. In contrast, caspase 3 activation in mitochondria-free cell lysates by granzyme (gr)B was inhibited equivalently by Us5 deletion and rescue viruses, suggesting that gJ is not required for HSV to inhibition this process. However, mitochondria-free lysates from transfected cells expressing Us5/gJ were protected from grB-induced caspase activation, suggesting that Us5/gJ is sufficient to inhibit this process. Transfected cells expressing Us5/gJ were also protected from death induced by incubation with purified grB and perforin. These findings suggest that HSV has a comprehensive set of immune evasion functions that antagonize both Fas ligand- and grB-mediated pathways of CTL-induced apoptosis. The understanding of HSV effects on killing by CTL effector mechanisms may shed light on the incomplete control of HSV infections by the immune system and may allow more rational approaches to the development of immune modulatory treatments for HSV infection.
Jerome
K R
KR
Department of Laboratory Medicine, University of Washington, Seattle, WA 98195, USA. kjerome@fhcrc.org
Chen
Z
Z
Lang
R
R
Torres
M R
MR
Hofmeister
J
J
Smith
S
S
Fox
R
R
Froelich
C J
CJ
Corey
L
L
D000818:Animals; D017209:Apoptosis; D061945:Caspase Inhibitors; D002522:Chlorocebus aethiops; D004789:Enzyme Activation; D053804:Granzymes; D018259:Herpesvirus 1, Human / Q000472:pathogenicity; D018258:Herpesvirus 2, Human / Q000472:pathogenicity; D006801:Humans; D019169:Jurkat Cells; D007700:Kinetics; D012697:Serine Endopeptidases / Q000494:pharmacology*; D018139:Simplexvirus / Q000472:pathogenicity*; D014162:Transfection; D014709:Vero Cells; D014759:Viral Envelope Proteins / Q000235:genetics / Q000494:pharmacology*; D019014:fas Receptor / Q000502:physiology*
D061945:Caspase Inhibitors; D014759:Viral Envelope Proteins; D019014:fas Receptor; C077970:glycoprotein J, herpesvirus simiae; C509213:GZMB protein, human; D053804:Granzymes; D012697:Serine Endopeptidases